AAV Curator™ Platform
A Proven Foundation to Deliver High-Quality Lentiviral Vectors
Highlights of the LVV Curator® Platform include:
Built on the Curator® Platform methodology that has supported over 100 AAV programs, offering a structured and repeatable framework that minimizes development risk.
Uses a clinically validated Curator® HEK293 cell line with established regulatory acceptance, helping to streamline development and build regulatory confidence.
Collaborative development beginning at project initiation, including design of experiments (DOE) and data-driven process optimization to establish robust processes faster.
Extends a commercially validated platform approach into lentiviral vector manufacturing, bringing consistency, scalability, and operational discipline to early-stage LVV programs.
Processes are designed with GMP requirements in mind from the outset, supported by unified cGMP quality systems aligned with commercial manufacturing standards.
Processes are designed with GMP requirements in mind from the outset, supported by unified cGMP quality systems aligned with commercial manufacturing standards.
LVV Curator® Platform Process
Optimization-By-Design™
Industrializing Gene Therapy Processes with a Reductionist, Holistic and Systematic Optimization Methodology Approach
Consistency in productivity and quality are evaluated at each stage of development and measured with enabling technologies.
Benefits of Our Platform Approach
Reduced Spending on Optimization
High Productivity and % Full Capsids driving production costs down
No MCB Generation Costs
No Tech Transfer Costs
No PreClinical/clinical Licensing Fees
Reduced time spent on opTimization
Off the Shelf (OTS) plasmids readily avaIlable
No MCB generatIon time
Supply Chain Already Established
NO TECH TRANSFER/DOCUMENTATION TIME
DMFs filed for Andelyn’s platform
Same equipment in non-GMP & GMP
Same quality systems
Integrated teams in Preclinical & Clinical